Clinical Trial

Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 17, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to compare the relative bioavailability, safety and tolerability of the first-generation and second-generation formulations of HRS9531 tablets, as well as to explore the safety, tolerability and pharmacokinetic characteristics of the second-generation formulation in terms of single-dose escalation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-27.
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT07150962
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Overweight or Obesity
Enrollment 168 participants
Start Date 2025-10-15
Primary Completion 2026-02 (estimated)
Study Completion 2026-09 (estimated)
Updated on ClinicalTrials.gov 2025-11-17